Correction to “Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome”

Abstract

Correction to “Zhang GL, Liu Y, Liu YF, Huang XT, Tao Y, Chen ZH, Lai HL. Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome. World J Diabetes 2024; 15: 724-734 [PMID: 38680706 DOI: 10.4239/wjd.v15.i4.724]”. In the original publication, the bands of p-AMPK and AMPK in Figure 8A were placed wrongly. This error has now been corrected. In addition, the statistical symbol for the last group on the graph on the right side of Figure 8A has been corrected to “c”; “&” was incorrect.

Key Words: Correction

Core Tip: In the original publication, the bands of p-AMPK and AMPK in Figure 8A were placed wrongly. This error has now been corrected. In addition, the statistical symbol for the last group on the graph on the right side of Figure 8A has been corrected to “c”; “&” was incorrect. We apologize for these errors and any confusion that they may have caused.

TO THE EDITOR

In this article[1], we placed the bands for p-AMPK and AMPK on the western blots in Figure 8A incorrectly. This error has now been corrected (Figure 1). In addition, the statistical symbol for the last group on the graph on the right side of Figure 8A has been corrected to “c” (Figure 1); “&” was incorrect. Importantly, the statistical analysis and conclusion of the article were based on the correct data, and therefore these inadvertent errors do not affect the scientific conclusions of the study. We sincerely apologize for these errors, which were identified during a thorough review of the published content.

Figure 1 Inhibition of AMPK abolished the beneficial effects of teneligliptin against high glucose in cardiomyocytes. Primary cardiomyocytes were treated with high glucose (30 mmol/L) with or without teneligliptin (5 μmol/L) and compound C (10 μM). A: Levels of p-AMPK. ^aP < 0.05 vs control group; ^bP < 0.05 vs high glucose 30 mmol/L group; ^cP < 0.05 vs high glucose 30 mmol/L + teneligliptin 5 μmol/L group, n = 5.